Send to

Choose Destination
Eur J Rheumatol. 2019 Apr 9. doi: 10.5152/eurjrheum.2019.18159. [Epub ahead of print]

Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma.

Author information

Department of Internal Medicine, Yale University School of Medicine, Connecticut, USA.
Department of Rheumatology, Yale New Haven Hospital, Connecticut, USA.


Checkpoint inhibitors are a novel option in the management of metastatic melanomas and many other malignancies. They are used to promote the activation of cytotoxic T-lymphocytes by inhibiting deactivation signals, enabling the immune response to the tumor. Numerous Immune-related adverse effects caused by checkpoint inhibitors have been reported in the literature. They are diverse in nature, and many are life threatening. We report a case of autoimmune myositis and myasthenia gravis following treatment with a combination of ipilimumab and nivolumab for metastatic melanoma.

Publication type

Publication type

Supplemental Content

Loading ...
Support Center